首页> 外文期刊>Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology >Noninvasive ventilation in immunocompromised pediatric patients: eight years of experience in a pediatric oncology intensive care unit.
【24h】

Noninvasive ventilation in immunocompromised pediatric patients: eight years of experience in a pediatric oncology intensive care unit.

机译:免疫功能低下的小儿患者的无创通气:在小儿肿瘤科重症监护室八年的经验。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: The experience of noninvasive positive pressure ventilation (NPPV) in the pediatric setting is limited. The aim of the present study is to retrospectively evaluate the effectiveness of NPPV in pediatric immunocompromised patient admitted in our PICU (Pediatric Intensive Care Unit) for acute respiratory failure. DESIGN/SETTING: Retrospective cohort study of children admitted to the PICU of Hospital do Cancer between June 1997 and May 2005 requiring ventilatory support. RESULTS: A total of 239 admissions were included. The first mechanical ventilation (MV) technique used was NPPV in 120 (50.2%) patients [noninvasive ventilation (NIV) group] and conventional MV in 119 (49.8%) [invasive ventilation (IV) group]; 25.8% of the patients from the NIV group subsequently required intubation. Patients in the IV group were more likely to be in a severe clinical status. Characteristics associated with severe clinical status were median value for therapeutic intervention scoring system score (37.5 points IV vs. 29 points NIV, P<0.0001), presence of >2 organs failure (63.6% IV vs. 36.4% NIV, P<0.0001), cardiac failure (62.5% IV vs. 37.5% NIV, P<0.0001), and septic shock (63.9% IV vs. 36.1% NIV, P<0.0001). Documented severe pulmonary disease was significantly higher (67.6%) in IV group, P=0.02. Baseline values of arterial pCO2, hypoxemia, arterial pH, and respiratory rate did not differ between the groups. Multivariate analysis showed that independent predictive factors for intubation were solid tumors (P=0.012), cardiovascular dysfunction (P<0.0001), and therapeutic intervention scoring system score >or=40 points (P=0.018). CONCLUSIONS: Our results encourage the use of NPPV as a first-line treatment in children with malignancies who develops acute respiratory failure, except in those with severe hemodynamic status.
机译:目的:小儿无创正压通气(NPPV)的经验有限。本研究的目的是回顾性评估NPPV对在我院重症监护病房(PICU)入院的小儿免疫功能低下患者急性呼吸衰竭的有效性。设计/地点:1997年6月至2005年5月间入院需要通气支持的儿童的回顾性队列研究。结果:总共239录取。最早使用的机械通气(MV)技术是NPPV治疗120例(50.2%)[无创通气(NIV)组]和常规MV 119例(49.8%)[有创通气(IV)组]。 NIV组中有25.8%的患者随后需要插管。 IV组患者更可能处于严重的临床状态。与严重临床状态相关的特征是治疗干预评分系统评分的中位数(IV为37.5分,NIV为29分,P <0.0001),器官衰竭> 2(IVIV为63.6%,NIV为36.4%,P <0.0001) ,心力衰竭(62.5%静脉注射vs. 37.5%NIV,P <0.0001)和败血性休克(63.9%静脉注射vs. 36.1%NIV,P <0.0001)。静脉注射组记录的严重肺部疾病明显更高(67.6%),P = 0.02。两组之间的动脉pCO2,低氧血症,动脉pH和呼吸频率的基线值没有差异。多变量分析显示,插管的独立预测因素是实体瘤(P = 0.012),心血管功能障碍(P <0.0001)和治疗干预评分系统评分>或= 40分(P = 0.018)。结论:我们的结果鼓励将NPPV用作发展为急性呼吸衰竭的恶性肿瘤儿童的一线治疗,但严重血液动力学状态的儿童除外。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号